Literature DB >> 10428088

Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.

D S Albers1, S J Augood, D M Martin, D G Standaert, J P Vonsattel, M F Beal.   

Abstract

Increased free radical production and oxidative stress have been proposed as pathogenic mechanisms in several neurodegenerative disorders. Free radicals interact with biological macromolecules, such as lipids, which can lead to lipid peroxidation. A well-established marker of oxidative damage to lipids is malondialdehyde (MDA). We measured tissue MDA levels in the subthalamic nucleus (STN) and cerebellum from 11 progressive supranuclear palsy (PSP) cases and 11 age-matched control cases using sensitive HPLC techniques. In PSP, a significant increase in tissue MDA levels was observed in the STN when compared with the age-matched control group. By contrast, no significant difference between tissue MDA content was observed in cerebellar tissue from the same PSP and age-matched control cases. These results indicate that lipid peroxidation may play a role in the pathogenesis of PSP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428088     DOI: 10.1046/j.1471-4159.1999.0730881.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

1.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

2.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Relationship between uric acid levels and progressive supranuclear palsy.

Authors:  David M Brody; Irene Litvan; Steve Warner; David E Riley; Deborah A Hall; Benzi M Kluger; David R Shprecher; Christopher R Cunningham
Journal:  Mov Disord       Date:  2016-02-18       Impact factor: 10.338

4.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

Review 5.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

6.  Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice.

Authors:  Ceyhan Elipenahli; Cliona Stack; Shari Jainuddin; Meri Gerges; Lichuan Yang; Anatoly Starkov; M Flint Beal; Magali Dumont
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  LX2343 alleviates cognitive impairments in AD model rats by inhibiting oxidative stress-induced neuronal apoptosis and tauopathy.

Authors:  Xiao-Dan Guo; Guang-Long Sun; Ting-Ting Zhou; Yi-Yang Wang; Xin Xu; Xiao-Fan Shi; Zhi-Yuan Zhu; Vatcharin Rukachaisirikul; Li-Hong Hu; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

8.  Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy.

Authors:  A Martínez; E Dalfó; G Muntané; I Ferrer
Journal:  J Neural Transm (Vienna)       Date:  2007-08-21       Impact factor: 3.575

9.  Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy.

Authors:  Victor Tapias; Shari Jainuddin; Manuj Ahuja; Cliona Stack; Ceyhan Elipenahli; Julie Vignisse; Meri Gerges; Natalia Starkova; Hui Xu; Anatoly A Starkov; Lucien Bettendorff; Dmitry M Hushpulian; Natalya A Smirnova; Irina G Gazaryan; Navneet A Kaidery; Sushama Wakade; Noel Y Calingasan; Bobby Thomas; Gary E Gibson; Magali Dumont; M Flint Beal
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

10.  Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Authors:  Hye-Jin Park; Kang-Woo Lee; Stephanie Oh; Run Yan; Jie Zhang; Thomas G Beach; Charles H Adler; Michael Voronkov; Steven P Braithwaite; Jeffry B Stock; M Maral Mouradian
Journal:  J Neuropathol Exp Neurol       Date:  2018-02-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.